Lilly’s insulin dip concerns analysts
Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.
Health Care & Life Sciences
Articles
Judge approves $90 million for Anthem plaintiffs
The settlement will go to 700,000 claimants in Indiana, Ohio, Kentucky and Connecticut, who said Anthem underpaid them when it converted in 2001 from policyholder ownership into publicly traded company WellPoint Inc.
Zimmer trims full-year forecast after quarterly profit falls
The Warsaw-based maker of orthopedic implants beat analysts’ estimates with its third-quarter earnings, but lowered its full-year forecast.
Amerigroup shareholders approve $4.9B sale to WellPoint
Shareholders of Amerigroup Corp. overwhelming approved the Virginia company’s sale for $4.9 billion to Indianapolis-based health insurer WellPoint Inc. in a vote on Tuesday. The vote clears the way for the acquisition to close before the end of the year.
Lilly misses analyst estimates, lowers profit forecast
Third-quarter earnings at Eli Lilly and Co. fell short of analysts’ expectations, and the Indianapolis-based drugmaker reduced its profit forecast by 4 cents per share for the remainder of the year.
Lilly CEO calls for life sciences research institute
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Lilly continues string of positive trials
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
Roche continues to restructure diabetes unit
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
Lilly says experimental diabetes drug outperformed rivals
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
Alzheimer’s prevention seen promising as drug cures fail
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Lawsuit claims Aspen Dental clinics operating illegally
A federal lawsuit filed in New York claims Aspen Dental Management and the private equity firm that controls it illegally operate dental clinics across the country. The company operates 29 offices in Indiana.
Indianapolis tech firms, hospitals discover mutual need
An initiative is matching tech entrepreneurs with hospital officials in the hope of solving health care problems.
Firm sees sterilization as fertile business ground
Indianapolis-based medical-device maker Catheter Research Inc. will receive a new kind of sterilization machine in December that it hopes will reduce costs and wait times for medical-device companies in the Midwest—including itself.
Lilly stomach-cancer drug helps survival, study finds
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.
Evans to lead AIT again as CEO leaves company
Ron Thieme, who took over as president and CEO of AIT Laboratories during a management shakeup earlier this year, is leaving the company, the Indianapolis-based firm announced Monday morning.
Can Lilly capitalize on Alzheimer’s breakthrough?
Eli Lilly and Co. has apparently made major medical history by being the first to develop a drug that alters the course of Alzheimer’s disease. But whether Lilly can be the first to make major money from a disease-altering Alzheimer’s drug is still in doubt.
WellPoint reorganizes into four business units
Separate Medicare and Medicaid divisions each will sell plans for those government-backed insurance programs. Another will handle commercial and individual business, and a specialty unit will provide dental, vision and disability coverage.
Small law firm sees faith in WellPoint class-action suit pay off
A federal judge in June granted preliminary approval to a deal under which WellPoint Inc. would pay $90 million to settle a lawsuit charging it undercompensated policyholders when it converted into a public company in 2001.
Lilly, Roche drugs chosen for Alzheimer’s prevention trial
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Lilly shares rise on Alzheimer’s study results
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.